Gainers
Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 36.2% to $0.2675 in pre-market trading. Baudax Bio, last month, announced a $4.2 million registered direct offering.
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and